NEW PUBLICATIONS UPTO OCT. 31ST 2015

NEW PUBLICATIONS UPTO OCT. 31ST 2015

1.	Cornea. 2015 Oct 27. [Epub ahead of print] Efficacy and Safety of Carbomer-Based Lipid-Containing Artificial Tear Formulations in Patients With Dry Eye Syndrome. Chung SH1, Lim SA, Tchach H. Author information:  1*Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; and †Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Abstract PURPOSE:  To evaluate the efficacy and safety profile of carbomer-based lipid-containing artificial tear formulations (CBLAT) in patients with dry eye syndrome. METHODS:  A multicenter parallel-group study was conducted in 412 patients with dry eye syndrome. Of these patients, 221 switched from using artificial tears to CBLAT (switching group) and 191 added CBLAT to their current treatment (add-on group). Ocular symptom scores, ocular staining grades, tear film breakup time (tBUT), Schirmer I test value, and Korean dry eye level (as defined by the Korean Corneal Disease Study Group guidelines) were evaluated at baseline and after 4 weeks of treatment. RESULTS:  After 4 weeks of treatment, ocular surface staining grade, tBUT, Schirmer I value, ocular irritation symptom scores, and the positive rate of visual symptom improved significantly in both groups. Mean reductions in ocular surface staining grades (-0.8 ± 0.9) and ocular irritation symptom scores (-0.8 ± 0.8) in the add-on group were significantly higher than those (-0.5 ± 0.8 and -0.6 ± 0.8) in the switching group (P < 0.01 and P < 0.05). The positive rate of visual symptoms (44.2%) in the add-on group was significantly higher than that (26.4%) in the switching group (P < 0.01). The decrease of Korean dry eye level was 30.1% in the switching group and 51.6% in the add-on group. More patients in the add-on group had decreased dry eye levels than those in the switching group (P < 0.0001). CONCLUSIONS:  CBLAT improves ocular surface staining grades, tBUT, Schirmer I values, and ocular symptoms in patients with dry eye syndrome.
	PMID: 26509769 [PubMed - as supplied by publisher]
	Similar articles

2.	J Ophthalmol. 2015;2015:396410. doi: 10.1155/2015/396410. Epub 2015 Oct 4. Human Serum Eye Drops in Eye Alterations: An Insight and a Critical Analysis. De Pascale MR1, Lanza M2, Sommese L1, Napoli C1. Author information:  1U.O.C. Immunohematology, Transfusion Medicine and Transplant Immunology, Regional Reference Laboratory of Transplant Immunology, Azienda Ospedaliera Universitaria (AOU), Second University of Naples, 80100 Naples, Italy. 2Multidisciplinary Department of Medical, Surgical and Dental Sciences, Second University of Naples, 80100 Naples, Italy. Abstract Human serum contains a physiological plethora of bioactive elements naturally released by activated platelets which might have a significant effect on the regeneration of corneal layers by stimulating the cell growth. This mechanism supported the use of human serum eye drops in some ocular diseases associated with dystrophic changes and alterations of the tear film, such as persistent corneal epithelial defects and dry eye syndrome. We focused our effort on potential benefits and limitations of the use of human serum eye drops when conventional therapies failed. We reviewed the recent literature by reporting published studies from 2010 to 2014. Despite the limited evaluated study populations, most of the clinical studies have confirmed that serum eye drop therapy is effective in corneal healing by reducing ocular symptom, particularly during the short-term follow-up. In addition, three recent published studies have shown the efficacy of the serum eye drop therapy in comparison to traditional ones in intractable patients. Besides, reported ongoing clinical studies confirmed the open debate regarding the use of biologic tools for cornea regeneration. Results from these studies might open novel challenges and perspectives in the therapy of such refractory patients.  PMCID: PMC4609447 Free PMC Article
	PMID: 26504592 [PubMed]
	Similar articles

3.	Clin Experiment Ophthalmol. 2015 Nov;43(8):707-10. doi: 10.1111/ceo.12658. To dry or not too dry: should we be more tolerant of stable subretinal fluid in patients receiving anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration? Razavi H1, Arnold J2, Guymer R1. Author information:  1Centre for Eye Research Australia (CERA), Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia. 2Marsden Eye Specialists, Parramatta, New South Wales, Australia.
	PMID: 26498270 [PubMed - in process]
	Similar articles

4.	Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5218-28. doi: 10.1167/iovs.15-17003. Role of Matrix Metalloproteinases 2 and 9 in Lacrimal Gland Disease in Animal Models of Sjögren's Syndrome. Aluri HS1, Kublin CL1, Thotakura S1, Armaos H1, Samizadeh M1, Hawley D1, Thomas WM2, Leavis P3, Makarenkova HP2, Zoukhri D1. Author information: 1Department of Diagnosis and Health Promotion Tufts University School of Dental Medicine, Boston, Massachusetts, United States. 2Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, California, United States. 3Department of Integrative Physiology and Pathobiology, Tufts University, Boston, Massachusetts, United States. Abstract PURPOSE:  Chronic inflammation of the lacrimal gland results in changes in the composition of the extracellular matrix (ECM), which is believed to compromise tissue repair. We hypothesized that increased production/activity of matrix metalloproteinases (MMPs), especially MMP-2 and -9, in inflamed lacrimal glands modifies the ECM environment, therefore disrupting tissue repair. METHODS:  The lacrimal glands from female MRL/lpr and male NOD mice along with their respective control strains were harvested and divided into three pieces and processed for histology, immunohistochemistry, zymography, Western blotting, and RNA analyses. In another study, MRL/lpr mice were treated for 5 weeks with a selective MMP2/9 inhibitor peptide or a control peptide. At the end of treatment, the lacrimal glands were excised and the tissue was processed as described above. RESULTS:  There was a 2.5- and 2.7-fold increase in MMP2 gene expression levels in MRL/lpr and NOD mice, respectively. Matrix metalloproteinase 2 and 9 enzymatic activities and protein expression levels were significantly upregulated in the lacrimal glands of MRL/lpr and NOD mice compared to controls. Treatment with the MMP2/9 inhibitor resulted in decreased activity of MMP-2 and -9 both in vitro and in vivo. Importantly, MMP2/9 inhibitor treatment of MRL/lpr mice improved aqueous tear production and resulted in reduced number and size of lymphocytic foci in diseased lacrimal glands. CONCLUSIONS:  We conclude that MMP2/9 expression and activity are elevated in lacrimal glands of two murine models of Sjögren's syndrome, suggesting that manipulation of MMP2/9 activity might be a potential therapeutic target in chronically inflamed lacrimal glands. PMCID: PMC4530776 [Available on 2016-02-01]
	PMID: 26244298 [PubMed - indexed for MEDLINE]
	Similar articles

5.	Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5175-81. doi: 10.1167/iovs.14-16307. Topical TSG-6 Administration Protects the Ocular Surface in Two Mouse Models of Inflammation-Related Dry Eye. Lee MJ1, Kim DH2, Ryu JS3, Ko AY3, Ko JH3, Kim MK2, Wee WR2, Khwarg SI4, Oh JY2. Author information:  1Department of Ophthalmology, Hallym University Sacred Heart Hospital, Anyang, Korea. 2Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea 3Department of Ophthalmology, Seoul National University Hospital, Seoul, Korea. 3Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea. 4Department of Ophthalmology, Seoul National University Hospital, Seoul, Korea. Abstract PURPOSE:  To investigate the therapeutic potential of TNF-α stimulated gene/protein (TSG)-6 in two mouse models of inflammation-mediated dry eye syndrome (DES). METHODS:  We created inflammation-mediated DES in mice by injecting concanavalin A (ConA; 10 mg/mL) into intraorbital and extraorbital lacrimal glands. Recombinant TSG-6 (1 μg in phosphate-buffered solution [PBS]) or the same volume of PBS was administered topically to eyes of the mice four times a day (QID) for 1 week. In parallel experiments, we topically applied TSG-6 (1 μg) or PBS QID to eyes of 12-week-old NOD.B10.H2b mice, a model for primary Sjögren's syndrome. Seven days later, tear production was measured, and the corneal surface was observed for epithelial defects. The number of goblet cells was evaluated in the forniceal conjunctiva. The levels of proinflammatory cytokines were analyzed in the cornea, conjunctiva, and lacrimal glands. Also, in vitro experiments were performed using cultures of corneal epithelial cells (CECs) to test the effects of TSG-6 on cell proliferation and migration. RESULTS:  Topical TSG-6 administration improved tear production and reduced corneal epithelial defects both in ConA-injected mice and NOD.B10.H2b mice. The conjunctival goblet cell density was higher in TSG-6-treated eyes than in PBS-treated eyes. The expression of proinflammatory cytokines in the cornea, conjunctiva, and intraorbital gland was repressed by TSG-6, while the levels of proinflammatory cytokines in the extraorbital gland were not changed. In vitro experiments revealed that TSG-6 promoted the migration of CECs, but did not affect the proliferation. CONCLUSIONS:  Topical TSG-6 protected the ocular surface by suppressing inflammation and promoting corneal epithelial wound healing.
	PMID: 26244293 [PubMed - indexed for MEDLINE]
	Similar articles

6.	Ann Rheum Dis. 2015 Sep;74(9):1645-50. doi: 10.1136/annrheumdis-2015-207499. Epub 2015 Jun 1. A review of salivary gland histopathology in primary Sjögren's syndrome with a focus on its potential as a clinical trials biomarker. Fisher BA1, Brown RM2, Bowman SJ3, Barone F 1. Author information:  1Rheumatology Research Group, University of Birmingham, Birmingham, UK Department of Rheumatology, University Hospitals Birmingham NHS Trust, Birmingham, UK. 2Department of Pathology, University Hospitals Birmingham NHS Trust, Birmingham, UK. 3Department of Rheumatology, University Hospitals Birmingham NHS Trust, Birmingham, UK. Abstract Salivary gland changes, characterised by a focal lymphocytic sialadenitits, play an important role in the diagnosis of primary Sjögren's syndrome (PSS) and were first described over 40 years ago. Recent evidence suggests that minor salivary gland biopsy may also provide information useful for prognostication and stratification, yet difficulties may arise in the histopathological interpretation and scoring, and evidence exists that reporting is variable. With the increasing number of actual and proposed clinical trials in PSS, we review the evidence that might support the role of histopathology as a biomarker for stratification and response to therapy and highlight areas where further validation work is required.  Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
	PMID: 26034044 [PubMed - indexed for MEDLINE]
	Similar articles

7.	Iran J Allergy Asthma Immunol. 2015 Apr;14(2):198-207. Cyclosporine A Suppresses the Activation of the Th17 Cells in Patients with Primary Sjögren's Syndrome. Wang K1, Shi L2, Yu Z3, Deng Z4, He A5, Li S6, Liu L7. Author information:  1The Central Laboratory, The First People's Hospital of Kunshan, Affiliated Hospital of Jiangsu University, Kunshan, 230251 China kaiwen_wang@yeah.net. 2The Central Laboratory, The First People's Hospital of Kunshan, Affiliated Hospital of Jiangsu University, Kunshan, 230251 China leis_08@126.com. 3The Central Laboratory, The First People's Hospital of Kunshan, Affiliated Hospital of Jiangsu University, Kunshan, 230251 China zongliang_yu@sohu.com. 4The Central Laboratory, The First People's Hospital of Kunshan, Affiliated Hospital of Jiangsu University, Kunshan, 230251 China zhiyong_deng@yeah.net. 5The Central Laboratory, The First People's Hospital of Kunshan, Affiliated Hospital of Jiangsu University, Kunshan, 230251 China aolin_he@sohu.com. 6The Central Laboratory, The First People's Hospital of Kunshan, Affiliated Hospital of Jiangsu University, Kunshan, 230251 China shasha_li14@126.com. 7Department of Rheumatology, The First People's Hospital of Kunshan, Affiliated Hospital of Jiangsu University, Kunshan, 230251 China leil.08@hotmail.com. Abstract Primary Sjögren's syndrome (pSS) is a common autoimmune disease involving abnormal Th17 activation. The aim of the current study was to investigate the immunosuppression effect of Cyclosporine A (Cys A), a potent immunosuppressor on the proliferation and activation of T cells, on the activation of Th17 cells. Blood samples from both inactive and active pSS patients as well as healthy controls were collected and serum and peripheral blood mononuclear cells (PBMCs) were collected and tested for IL-17 and RORγt expression. Subsequently, PBMCs were treated in vitro with Cys A in a series of doses and incubation time and the effect of Cys A on inhibiting Th17 activation was tested by measuring IL-17 and RORγt expression. IL-17 in both serum and PBMCs as well as RORγt in PBMCs from active pSS patients were significantly elevated on both the mRNA and protein levels comparing to those from both inactive pSS patients and healthy controlCys A in the final concentration of 80ng/ml and the treatment time of 24h showed strong inhibition effect on the expression of IL-17 and RORγt in PBMCs from active pSS patients. However, Cys A in various doses and incubation times did not show much impact on inhibiting IL-17 as well as RORγt expression in PBMCs from healthy donors and inactive pSS patients. Cys A possesses the capability in immunosuppressing the activation of Th17 cells, suggesting that Cys A may be a potential treatment for pSS and maybe other autoimmune diseases.  Free Article
	PMID: 25780886 [PubMed - indexed for MEDLINE]
	Similar articles

8.	Mult Scler. 2014 Sep;20(10):1413-6. doi: 10.1177/1352458514540834. Epub 2014 Jul 1. A case of pathology-proven neuromyelitis optica spectrum disorder with Sjögren syndrome manifesting aphasia and apraxia due to a localized cerebral white matter lesion. Sawada J1, Orimoto R2, Misu T3, Katayama T4, Aizawa H5, Asanome A4, Takahashi K4, Saito T4, Anei R2, Kamada K2, Miyokawa N2, Takahashi T3, Fujihara K3, Hasebe N4. Author information:  1Division of Neurology, Asahikawa Medical University, Japan sawadajun@gmail.com. 2Asahikawa Medical University, Japan. 3Tohoku University Graduate School of Medicine, Japan. 4Division of Neurology, Asahikawa Medical University, Japan. 5Tokyo Medical University, Japan. Abstract A woman with Sjögren syndrome manifesting as aphasia with a left deep cerebral white matter lesion tested positive for anti-aquaporin 4 (AQP4) antibody. Open biopsy of the lesion revealed active demyelination with edematous changes and the preservation of most axons, indicating a non-necrotic demyelinating lesion. Immunostaining for AQP4 was diffusely lost, whereas the loss of glial fibrillary acidic protein immunostaining was limited but with highly degenerated astrocytic foot processes in perivascular areas. These results suggested neuromyelitis optica spectrum disorder (NMOSD) pathology rather than Sjögren-related vasculitis. Only cerebral cortical symptoms with a cerebral white matter lesion could be observed in NMOSDs.  © The Author(s), 2014.
	PMID: 24986696 [PubMed - indexed for MEDLINE]
	Similar articles